We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-5.58%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$360M
AUM Growth
-$12.6M
Cap. Flow
+$26.7M
Cap. Flow %
7.41%
Top 10 Hldgs %
69.65%
Holding
41
New
4
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.7M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$15.1M
3
NTLA icon
Intellia Therapeutics
NTLA
+$7.11M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$3.31M
5
GERN icon
Geron
GERN
+$3.23M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$9.43M
2
AXSM icon
Axsome Therapeutics
AXSM
+$4.13M
3
RLMD icon
Relmada Therapeutics
RLMD
+$3.73M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.67M
5
CYTK icon
Cytokinetics
CYTK
+$1.21M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INZY
26
DELISTED
Inozyme Pharma
INZY
$3.17M 0.88%
664,980
+370,000
+125% +$1.61M
ONCR
27
DELISTED
Oncorus, Inc.
ONCR
$3M 0.83%
2,377,031
– –
RVMD icon
28
Revolution Medicines
RVMD
$44.6B
$2.85M 0.79%
146,041
– –
ADCT icon
29
ADC Therapeutics
ADCT
$146M
$2.66M 0.74%
334,384
– –
KRTX
30
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.53M 0.7%
20,000
– –
PRVB
31
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$2.37M 0.66%
+592,435
New +$2.81M
EPIX
32
DELISTED
ESSA Pharma
EPIX
$2.08M 0.58%
660,892
– –
PHAT icon
33
Phathom Pharmaceuticals
PHAT
$743M
$1.63M 0.45%
193,326
– –
NEO icon
34
NeoGenomics
NEO
$2.32B
$1.1M 0.31%
135,573
– –
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
$1.01M 0.28%
412,363
– –
TECX
36
Tectonic Therapeutic
TECX
$696M
$596K 0.17%
53,993
– –
BDTX icon
37
Black Diamond Therapeutics
BDTX
$128M
$590K 0.16%
239,888
– –
ACAD icon
38
Acadia Pharmaceuticals
ACAD
$5.02B
– –
-151,750
Closed -$3.67M
AXSM icon
39
Axsome Therapeutics
AXSM
$10.4B
– –
-99,834
Closed -$4.13M
RLMD icon
40
Relmada Therapeutics
RLMD
$462M
– –
-138,000
Closed -$3.73M
TPTX
41
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-351,350
Closed -$9.43M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q2 2022 Portfolio in Review

As of Q2 2022, MPM BioImpact held 41 positions worth $360M, down 3.4% from $373M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

MPM BioImpact deployed $26.7M of net new capital in Q2 2022, opening 4 new positions and adding to 3 existing holdings. Its largest new stake was Iovance Biotherapeutics: 1,200,000 shares worth $13.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cytokinetics, an estimated $1.21M trimmed.

  • MPM BioImpact's largest Q2 2022 buy was Iovance Biotherapeutics: 1,200,000 shares worth $13.2M.
  • MPM BioImpact added most to Intellia Therapeutics in Q2 2022, an estimated $7.11M increase.
  • MPM BioImpact's biggest Q2 2022 reduction was Cytokinetics, cutting an estimated $1.21M.
  • MPM BioImpact fully exited Turning Point Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $9.43M.
  • MPM BioImpact's ten largest holdings make up 70% of its $360M portfolio in Q2 2022.
  • MPM BioImpact opened 4 new positions and closed 4 in Q2 2022.
  • MPM BioImpact's portfolio value fell 3.4% quarter-over-quarter to $360M.

Based on MPM BioImpact's 13F filing for Q2 2022, filed 11 Aug 2022.